Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients
NCT06657859
·
clinicaltrials.gov ↗
PHASE2
Phase
ENROLLING_BY_INVITATION
Status
90
Enrollment
INDUSTRY
Sponsor class
Conditions
Pmm2-CDG
Phosphomannomutase 2 Deficiency
Interventions
DRUG:
GLM101
Sponsor
Glycomine, Inc.